Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two antibiotic treatment strategies for adults hospitalized with suspected community-acquired sepsis. The study compares empirical combination therapy using gentamicin with narrow spectrum betalactams penicillin, ampicillin, or cloxacillin against empirical therapy with broad spectrum betalactams cefotaxime or piperacillin-tazobactam. The goal is to determine if the combination therapy is as safe as broad spectrum therapy, particularly regarding kidney injury and death, while also examining its impact on antibiotic resistance and the gut microbiome. Participants are randomly assigned to receive either gentamicin plus a narrow spectrum betalactam or one of the broad spectrum betalactams as empirical treatment for suspected sepsis. Treatments are given according to hospital protocols during the initial management of sepsis. The study is designed as a pragmatic clinical trial with parallel groups and does not use blinding. The investigation spans up to 30 days after randomization for primary outcomes, with follow-up during the hospital stay and after discharge. During the study, participants are monitored for various outcomes including 30-day mortality, acute kidney injury within 30 days, duration of hospital and intensive care stays, ventilator and vasopressor therapy use, hospital readmissions, and antibiotic treatment duration. Safety and treatment effects are assessed through clinical observations and data collected during hospitalization and up to 30 days after discharge. The total participation time covers the initial hospital treatment period and the 30-day follow-up after randomization.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of stopping antibiotic treatment early in adults hospitalized with respiratory viral infections. This study focuses on patients with moderately severe disease who test positive for respiratory viruses such as influenza, respiratory syncytial virus, parainfluenza virus, or human metapneumovirus. The goal is to determine if early discontinuation of antibiotics leads to similar clinical outcomes compared to continuing antibiotic therapy, aiming to reduce unnecessary antibiotic use and combat antimicrobial resistance. Participants are randomly assigned to either stop antibiotic therapy as started by their admitting physician or to continue antibiotic therapy without changes. The study monitors early clinical response at 120 hours after randomization, defined by survival with symptom improvement and no need for rescue antibiotics. Secondary assessments include mortality rates, hospital stay duration, antibiotic use, and readmission rates, all measured during hospital admission and up to 30 days after discharge. During the trial, participants undergo nasopharyngeal swab testing to confirm viral infection and are monitored closely for symptoms, survival, and antibiotic use. Researchers evaluate clinical response at 120 hours and track outcomes such as mortality, hospital stay length, and antibiotic doses until discharge and 30 days later. The study aims to gather detailed safety and efficacy data over the hospital stay and follow-up period, supporting more targeted antibiotic use in viral respiratory infections.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
Researchers are comparing two types of reverse shoulder replacements to see which provides better shoulder function after two years. This study focuses on patients who need shoulder replacement due to conditions like osteoarthritis or rotator cuff issues. The study aims to find out if a bone transplant method, called BIO-RSA, improves outcomes compared to the conventional reverse shoulder arthroplasty RSA. The trial involves 130 patients randomly assigned to receive either the BIO-RSA or the conventional RSA procedure. BIO-RSA includes placing a bone graft under the shoulder implant to increase joint stability and range of motion, potentially reducing complications like scapular notching. The study is blinded and conducted across multiple hospitals to compare these two surgical methods over a two-year period. Participants will have their shoulder function evaluated before surgery and at 3, 12, and 24 months afterward using patient questionnaires, physical exams by physiotherapists, and CT scans reviewed by radiologists. The main measure is the change in the Western Ontario Osteoarthritis Shoulder WOOS score after 24 months. Other assessments include quality of life, shoulder motion, and pain. The study will monitor participants for two years to gather comprehensive data on outcomes and complications.
Actively Recruiting
This research aims to explore the genetic causes related to the development of Amyotrophic Lateral Sclerosis ALS in Norway. The study focuses on individuals diagnosed with probable or definite ALS according to the El-Escorial criteria. Understanding genetic factors may help in better characterizing the disease and its risk factors over time. Participants diagnosed with ALS will be followed through the Norwegian health-care system. After giving informed consent, they will complete a brief questionnaire about their family history and provide a blood sample. These samples, along with clinical information and consent forms, are sent to the Department of Medical Genetics at Telemark Hospital Trust for ongoing genetic analysis throughout the recruitment period. Participants may choose to receive their genetic results as part of a diagnostic process. During the study, participants will be involved in providing blood samples and completing questionnaires. Researchers will analyze genetic data to identify gene frequency, new ALS genes, and genetic risk factors between 2020 and 2030. The study involves observation only, with no additional treatments. Participation includes genetic testing and data collection to better understand ALS genetics, with the study continuing until 2035.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating treatment options for older men aged 75 years or older with high-risk, non-metastatic prostate cancer. The study aims to compare immediate curative treatments like radiotherapy combined with hormone therapy or surgery to conservative approaches such as observation or hormone therapy. This trial addresses the uncertainty about whether immediate curative treatment offers survival benefits in older patients similar to those seen in younger men, while also considering quality of life and cost-effectiveness. Participants randomized to the immediate curative therapy group will receive either radiotherapy plus hormone therapy or surgery based on patient preference, with radiotherapy plus hormone therapy being the standard. Those assigned to the conservative group will be observed or receive hormone therapy depending on disease status, with further treatment given based on disease progression. This phase 3 randomized trial compares these two approaches over an extended period. Throughout the study, participants will be regularly evaluated for overall survival and disease burden up to 10 years after recruitment ends. Secondary assessments include monitoring urinary, bowel, and prostate cancer-related symptoms, quality of life, functional status, and the need for additional therapies. The study involves ongoing monitoring to understand long-term outcomes and side effects, supporting comprehensive assessment of treatment impact for this older population.
Actively Recruiting
Researchers are evaluating the effectiveness of approved anti-cancer drugs used outside their usual indication for patients with advanced cancer who have specific molecular changes identified through diagnostic testing. This nationwide, phase 2 clinical trial in Norway uses a combined umbrella and basket design with a Simon two-stage model to study various drug and biomarker combinations across different cancer types. Biological samples will be collected at presentation, during treatment, and upon disease progression to better understand drug response and resistance through advanced genetic analyses, including whole genome sequencing. The study involves patients who have advanced cancers no longer benefiting from standard treatments and who have molecular profiles indicating potential benefit from one of the approved drugs in the trial. Participants will receive treatment with drugs such as atezolizumab, alectinib, and others, used beyond their usual indications based on biomarker profiles. Treatment plans are guided by a national molecular tumor board, and fresh tumor biopsies will be collected before treatment to support biomarker studies. New patient cohorts may be opened as needed based on molecular subgroups and drug availability. Participants will be monitored for tumor response, progression-free survival, overall survival, and treatment duration. Data on treatment toxicity will be collected, and all treatment and outcome information, along with molecular screening results, will be reported to the Cancer Registry of Norway. Long-term follow-up will also use national registries to track patient outcomes. Patients who are screened but not enrolled will be followed for 16 weeks to monitor survival and disease progression.
Actively Recruiting
Researchers are conducting a global, multicenter, randomized, double-blind, placebo-controlled pivotal phase III study to evaluate overall survival in patients with newly diagnosed higher-risk myelodysplastic syndrome HR-MDS. The study compares the combination of lisaftoclax APG-2575 and azacitidine AZA against placebo combined with azacitidine. This trial aims to better understand treatment outcomes in this patient group. Participants receive either lisaftoclax orally once daily combined with azacitidine administered by hypodermic or intravenous injection once daily, or placebo orally once daily combined with azacitidine. The study includes two groups running in parallel. Treatment and follow-up continue for up to five years to assess long-term outcomes. During the study, participants will undergo regular evaluations including assessments of overall survival and safety, specifically monitoring adverse events over the five-year period. Participants must be able to complete study procedures and follow-up examinations. The study involves informed consent and ongoing monitoring to ensure participant safety and adherence.
1-10 of 14
1